22, 2016 (GLOBE NEWSWIRE) — Horizon Pharma plc ( HZNP ), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, and its affiliateHorizon Therapeutics Canada Limited, today announced that QUINSAIR (levofloxacin inhalation solution)is now available in Canada for the management of chronic pulmonary infections due toPseudomonas aeruginosain adult patients with cystic fibrosis (CF). QUINSAIR is the first inhaled fluoroquinolone antibiotic to receive marketing authorization from Health Canada. Prevalence of Pseudomonas aeruginosa is high among people with cystic fibrosis and chronic management is often required after a patient is infected with these bacteria, saidJared Rhines, vice president and general manager,Canada, LATAM and APAC, Horizon Pharma. Horizon has a long-term commitment to people living with rare diseases, and were looking forward to working with healthcare professionals and patient organizations that address the needs of the Canadian cystic fibrosis community at risk for these insidious infections. CF is a rare, life-threatening genetic disease affecting approximately 75,000 people worldwide,1 and more than 4,100 people in Canada.2 It is the most common fatal genetic disease among Canadian young adults, and primarily affects the digestive system and lungs. While disease severity differs among people living with CF, persistent and ongoing infections in the lungs are the most frequent cause of death.3 Pseudomonas aeruginosa is one of the most common bacteria causing lung infections in people living with CF.4 It is very important that healthcare professionals in Canada have access to a variety of medicines for people with cystic fibrosis dealing with Pseudomonas aeruginosa infections, said Norma Beauchamp, president and chief executive officer, Cystic Fibrosis Canada. Once established in the airways, this bacteria becomes very difficult to eliminate, often requiring aggressive treatment with multiple therapies. QUINSAIR provides an inhaled option and were pleased that it is now available in Canada. For more information about the availability of QUINSAIR in Canada, including Horizons patient support programs, please call 1-844-823-4226. Horizon acquired QUINSAIR as part of its acquisition of Raptor Pharmaceutical Corp. in October 2016. About QUINSAIR QUINSAIR is a proprietary inhaled formulation of levofloxacin, a fluoroquinolone antibiotic, which is approved in Canada for the management of chronic pulmonary infections due toPseudomonas aeruginosain adult patients with CF. Administration of QUINSAIR with the high efficiency ZirelaNebulizer System (PARI Pharma GmbH) allows for the direct delivery of high concentrations of active drug to the site of infection in approximately five minutes. QUINSAIR is contraindicated in patients with hypersensitivity to levofloxacin, a history of tendon disorders related to fluoroquinolones and patients who may be pregnant or breast feeding. QUINSAIR’s safety was evaluated in two double-blind, placebo-controlled studies and an active comparator study in which the most frequently reported adverse reactions were cough/productive cough, dysgeusia and sputum increase. For More Information: Please consult the product monograph at http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp for important information relating to warnings, precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this press release.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/horizon-pharma-plc-announces-availability-120000567.html
To be more concise, what is Batavias brand? Thats what the researchers, strategists and creative folks at Sparc want to know. The graphic design firm will survey Batavia residents to find out, and then will develop a community brand that can be used for marketing the city. You need to stand out from your competitors, said Daniel Grove, a strategist and consultant with the firm. The Winnetka-based company has been retained by the city to develop the branding plan, which may or may not involve the creation of a new logo for Batavia. Sparc officials told city aldermen at a recent committee meeting that the project will be complete and ready to implement by the first day of summer. Seventh Ward Alderman Dave Brown said hes keeping an open mind, but said he really did not see the need for the project, or replacing the citys well-established logo, which features a windmill, Fermilabs Wilson Hall, the name Batavia and the motto City of Energy. I dont want to forget our history or where we came from, Brown said. The team from Sparc sought to reassure council members that the whole idea is to create an authentic reflection of the community. It would be a mistake to try to be something youre not, strategist and writer Mary Ann Rood said.medical job interview skills
For the original version including any supplementary images or video, visit http://www.kcchronicle.com/2016/12/16/design-firm-to-survey-batavia-community-on-its-identity/a2t5api/
There are more issues than just having a sizeable amount of funds to start up your own recruitment firm. As well as establishing how much history you bring forward into the new application, you still have a decision to make on where to store historical data. The National Resident Matching Program NRMP® Scramble is an often times confusing process that tends to generate a lot of questions. It tells the reader who you are in a single concise way that encompasses the very essence of your abilities. Every category of products you sell, you receive a percentage of commission. If done correctly, it could look impressively skilful; if not, it could be hideous. Everyone knows the standard resume needs a career objective. checkThen, there are also sales jobs in Dammam in the oil and petrol industry.